We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 09, 2022

A Novel Prognostic Model Predicting Overall Survival in Patients With mCRPC Receiving Standard Chemotherapy

The Prostate

 

Additional Info

The Prostate
A novel prognostic model predicting overall survival in patients with metastatic castration-resistant prostate cancer receiving standard chemotherapy: A multi-trial cohort analysis
Prostate 2022 Jul 05;[EPub Ahead of Print], D Modonutti, SE Majdalany, N Corsi, P Li, A Sood, D Dalela, ML Jamil, C Hwang, M Menon, CG Rogers, QD Trinh, G Novara, F Abdollah

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading